RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis

Schaeffer, Samantha; Gupta, Bhavana; Calatayud, Anna-Line; Caldéraro, Julien; Caruso, Stefano; Hirsch, Théo Z.; Pelletier, Laura; Zucman‐Rossi, Jessica; Rebouissou, Sandra

doi:10.1016/j.jhep.2023.05.004

Cited by 3 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have demonstrated that adenovirus-mediated transfer of wild-type AXIN1 gene can elicit apoptosis in HCC and CRC cells that have accumulated β-catenin due to APC, CTNNB1 or AXIN1 mutation [89]. RSK2-inactivating mutations frequently co-occur with AXIN1-inactivating or β-cateninactivating mutations, which play a synergistic role in promoting HCC development [92]. RNF43, as a E3 ubiquitin-protein ligase, exerts inhibitory effect on Wnt/β-catenin by mediating FZD ubiquitination followed by lysosomal degradation.…”

Section: Mechanisms Of Activation Of the Wnt/β-catenin Signaling Path...mentioning

confidence: 99%

Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy

Song,

Gao,

Bao

et al. 2024

J Hematol Oncol

View full text Add to dashboard Cite

The Wnt/β-catenin signaling pathway plays a crucial role in various physiological processes, encompassing development, tissue homeostasis, and cell proliferation. Under normal physiological conditions, the Wnt/β-catenin signaling pathway is meticulously regulated. However, aberrant activation of this pathway and downstream target genes can occur due to mutations in key components of the Wnt/β-catenin pathway, epigenetic modifications, and crosstalk with other signaling pathways. Consequently, these dysregulations contribute significantly to tumor initiation and progression. Therapies targeting the Wnt/β-catenin signaling transduction have exhibited promising prospects and potential for tumor treatment. An increasing number of medications targeting this pathway are continuously being developed and validated. This comprehensive review aims to summarize the latest advances in our understanding of the role played by the Wnt/β-catenin signaling pathway in carcinogenesis and targeted therapy, providing valuable insights into acknowledging current opportunities and challenges associated with targeting this signaling pathway in cancer research and treatment.

show abstract

Section: Mechanisms Of Activation Of the Wnt/β-catenin Signaling Path...mentioning

confidence: 99%

Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy

Song,

Gao,

Bao

et al. 2024

J Hematol Oncol

View full text Add to dashboard Cite

show abstract

Liver cancer wars: plant-derived polyphenols strike back

Niu,

Zhang,

Okolo

2024

Med Oncol

View full text Add to dashboard Cite

Exploration of ANKRD27 as an immune-related prognostic factor in pan-cancer and hepatocellular carcinoma

Shen,

Fan,

Ying

et al. 2025

Front. Oncol.

View full text Add to dashboard Cite

IntroductionAnkyrin repeat domain 27 (ANKRD27) has been found to be associated with certain cancers. However, its clinical potential in pan-cancer remains unclear.MethodsPublic datasets (TCGA and GTEx) were applied to analyze ANKRD27 expression in multiple cancer types and its correlations with immune scores, immune checkpoint genes, and immune modulatory genes. We also examined ANKRD27 expression in hepatocellular carcinoma (HCC) patients using TCGA and GSE14520 datasets. The upregulation of ANKRD27 was verified via qRT-PCR in vitro. Based on TCGA-HCC, external, and GSE14520 cohorts, the associations between ANKRD27 expression and survival outcome were explored via the Kaplan-Meier survival curve. The effects of ANKRD27 reduction on HCC cell growth, movement, and invasion were evaluated by CCK-8, Wound healing, and Transwell assays.ResultsANKRD27 exhibited aberrant expression in multiple cancers and was correlated with immune traits, including immune infiltration, immune checkpoint genes, and immune modulatory genes. Elevated expression of ANKRD27 was found in TCGA-HCC and GSE14520 cohorts and was confirmed in HCC cell lines. HCC patients with high ANKRD27 expression had poorer prognosis. In vitro, reducing ANKRD27 decreased the capability of proliferation, migration, and invasion in HCC cells. High ANKRD27 expression was associated with sensitivity to certain drugs.ConclusionANKRD27 displays abnormal levels of expression in different cancer types and is linked to immune status in cancer. Furthermore, ANKRD27 may serve as a prognostic predictor for HCC.

show abstract

RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis

Cited by 3 publications

References 37 publications

Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy

Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy

Liver cancer wars: plant-derived polyphenols strike back

Exploration of ANKRD27 as an immune-related prognostic factor in pan-cancer and hepatocellular carcinoma

Contact Info

Product

Resources

About